We caught up with Dr. Peter Bossuyt (Imelda General Hospital, Bonheiden, Belgium) to discuss the post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY studies which investigated risankizumab therapy by baseline Crohn’s Disease location.
The abstract ‘Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies’ (Presentation no. OP40) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- How does disease location affect treatment outcomes in Crohn’s disease? (0:13)
- Could you give us a brief overview of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies and their findings? (0:56)
- What was the rationale for the current post-hoc analysis of these study data? (2:00)
- What were the findings of the analysis? (3:14)
- How will these findings impact on the future clinical use of risankizumab in patients with Crohn’s disease? (4:58)
Disclosures: Peter Bossuyt discloses receiving financial support for research from AbbVie, Amgen, Janssen, Mundipharma, Mylan, and Pfizer; lecture fees from AbbVie, Celltrion, Janssen, Pfizer, and Takeda; and advisory board fees from AbbVie, Arena pharmaceuticals, Bristol Myers Squibb, Hospira, Janssen, Lilly, Merck, Mundipharma, Pentax Medical, Pfizer, PSI CRO, Roche, Sandoz, and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!